Martine Rothblatt Sells 9,500 Shares of United Therapeutics (NASDAQ:UTHR) Stock

United Therapeutics Corporation (NASDAQ:UTHR) CEO Martine Rothblatt sold 9,500 shares of United Therapeutics stock in a transaction on Wednesday, March 4th. The stock was sold at an average price of $489.91, for a total transaction of $4,654,145.00. Following the sale, the chief executive officer directly owned 130 shares of the company’s stock, valued at $63,688.30. This represents a 98.65% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink.

United Therapeutics Stock Performance

Shares of NASDAQ:UTHR opened at $478.16 on Friday. The firm has a market capitalization of $20.96 billion, a PE ratio of 17.14, a price-to-earnings-growth ratio of 1.75 and a beta of 0.84. United Therapeutics Corporation has a 52-week low of $266.98 and a 52-week high of $537.19. The firm has a fifty day moving average of $482.51 and a 200 day moving average of $452.28.

United Therapeutics (NASDAQ:UTHR) last released its quarterly earnings results on Wednesday, February 25th. The biotechnology company reported $7.70 earnings per share for the quarter, beating analysts’ consensus estimates of $6.78 by $0.92. United Therapeutics had a return on equity of 19.30% and a net margin of 41.94%.The business had revenue of $790.20 million for the quarter, compared to the consensus estimate of $814.80 million. During the same quarter last year, the business posted $6.19 earnings per share. The company’s revenue for the quarter was up 7.4% on a year-over-year basis. On average, sell-side analysts forecast that United Therapeutics Corporation will post 24.48 EPS for the current fiscal year.

Analyst Ratings Changes

A number of analysts recently weighed in on the company. Royal Bank Of Canada boosted their target price on United Therapeutics from $587.00 to $643.00 and gave the stock an “outperform” rating in a research report on Thursday, February 26th. Jefferies Financial Group reiterated a “buy” rating on shares of United Therapeutics in a research report on Monday. TD Cowen lifted their price target on shares of United Therapeutics from $525.00 to $575.00 and gave the stock a “buy” rating in a research note on Wednesday, February 25th. UBS Group boosted their price objective on shares of United Therapeutics from $655.00 to $705.00 and gave the stock a “buy” rating in a report on Thursday. Finally, Bank of America reaffirmed a “neutral” rating on shares of United Therapeutics in a research note on Wednesday, February 25th. Nine research analysts have rated the stock with a Buy rating and three have assigned a Hold rating to the company’s stock. According to data from MarketBeat, United Therapeutics has a consensus rating of “Moderate Buy” and a consensus price target of $539.00.

Key Headlines Impacting United Therapeutics

Here are the key news stories impacting United Therapeutics this week:

• Positive Sentiment: UBS raised its price target on UTHR from $655 to $705 and kept a Buy rating — a notable analyst endorsement implying material upside that could attract buyers. Read More.
• Neutral Sentiment: Multiple sell‑side firms have recently increased targets and reiterated Buy/outperform views (Oppenheimer, HC Wainwright, TD Cowen); consensus remains a “Moderate Buy” with a mid‑range price target, supporting a constructive medium‑term thesis. Read More.
• Negative Sentiment: A wave of insider selling this week is pressuring sentiment: CEO Martine Rothblatt sold 9,500 shares (~$4.65M), and several directors/executives (Ray Kurzweil, Paul Mahon, Tommy G. Thompson and others) also sold blocks at roughly $483–$490 per share. These large, concentrated disposals can prompt near‑term weakness even if insiders retain stakes. Read More. Read More.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently made changes to their positions in the company. Torren Management LLC purchased a new position in shares of United Therapeutics in the fourth quarter worth $26,000. Activest Wealth Management boosted its position in United Therapeutics by 1,400.0% during the 4th quarter. Activest Wealth Management now owns 60 shares of the biotechnology company’s stock valued at $29,000 after buying an additional 56 shares during the period. WealthCollab LLC grew its holdings in United Therapeutics by 55.9% in the 2nd quarter. WealthCollab LLC now owns 106 shares of the biotechnology company’s stock worth $30,000 after acquiring an additional 38 shares during the last quarter. Rakuten Securities Inc. increased its position in shares of United Therapeutics by 76.7% in the second quarter. Rakuten Securities Inc. now owns 106 shares of the biotechnology company’s stock valued at $30,000 after acquiring an additional 46 shares during the period. Finally, Entrust Financial LLC purchased a new position in shares of United Therapeutics in the fourth quarter valued at about $31,000. Institutional investors own 94.08% of the company’s stock.

About United Therapeutics

United Therapeutics Corporation (NASDAQ: UTHR) is a biotechnology company dedicated to the development and commercialization of unique products to address life-threatening illnesses. The company’s primary focus has been on pulmonary arterial hypertension (PAH), where it has launched several therapies designed to improve functional capacity and quality of life for patients. Its marketed products include continuous infusion treprostinil (Remodulin), inhaled treprostinil (Tyvaso), oral treprostinil (Orenitram) and tadalafil (Adcirca), each tailored to different modes of administration and patient needs.